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Abstract
Background
Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal tox-
icity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral
characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment
with those of patients initiating DAA-based treatment.
Methods
ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which
enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units.
Both clinical/biological and socio-behavioral data were collected during follow-up. We
selected patients with socio-behavioral data available before HCV treatment initiation.
Results
A total of 580 patients were included in this analysis. Of these, 347 initiated PEG-IFN-based
treatment, and 233 DAA-based treatment. There were significant differences regarding
patient mean age (45 years±6 for the PEG-IFN group vs. 52 years±8 for the DAA group,
p<0.001), unstable housing (21.4% vs. 11.2%, p = 0.0016), drug use (44.7% vs. 29.6%, p =
0.0003), regular or daily use of cannabis (24.3% vs. 15.6%, p = 0.0002), a history of drug
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injection (68.9% vs 39.0%, p<0.0001) and significant liver fibrosis (62.4% vs 72.3%, p =
0.0293). In multivariable analysis, patients initiating DAA-based treatment were older than
their PEG-IFN-based treatment counterparts (aOR = 1.17; 95%CI [1.13; 1.22]). Patients
receiving DAA treatment were less likely to report unstable housing (0.46 [0.24; 0.88]), can-
nabis use (regular or daily use:0.50 [0.28; 0.91]; non-regular use: 0.41 [0.22; 0.77]), and a
history of drug injection (0.19 [0.12; 0.31]).
Conclusion
It is possible that a majority of patients who had socio-economic problems and/or a history
of drug injection and/or a non-advanced disease stage were already treated for HCV in the
PEG-IFN era. Today, patients with unstable housing conditions are prescribed DAA less fre-
quently than other populations. As HCV treatment is prevention, improving access to DAA
remains a major clinical and public health strategy, in particular for individuals with high-risk
behaviors.
Introduction
Chronic hepatitis C virus (HCV) infection is an endemic disease that affects approximately 71
million people worldwide [1], with significant regional variability. In recent decades, great
progress has been made in treating chronic HCV infection. First-generation treatments were
mainly composed of pegylated interferon (PEG-IFN) and ribavirin and were administered for
at least 48 weeks. The response rate was 60–70% for genotypes 2 and 3 but lower for genotypes
1 and 4 [2]. Moreover, PEG-IFN-based treatments had significant side effects including flu-
like symptoms, asthenia, neuropsychiatric symptoms, hematological toxicity, rashes, and more
lifetime complications [3,4].
The recent emergence of a new generation of treatments—direct-acting antivirals (DAA)–
constitutes a revolution in HCV care. DAA are more effective and better tolerated than
PEG-IFN and ribavirin, and in 8 to 24 weeks a sustained virological response (SVR) is
obtained in over 90% of treated patients, including previously difficult-to-treat patients and
HIV-HCV co-infected patients [5–8].
However, the costs of DAA are very high, and access varies across global regions. Even in
countries with a universal health system, restricted access is not uncommon [9,10]. Germany
and the United Kingdom are two countries that immediately implemented universal access to
DAA treatment [11], and all patients infected with HCV are treated unconditionally. In both
the PEG-IFN and DAA eras, in some countries, the most common barriers to initiating HCV
treatment in HIV-HCV co-infected patients include psychoactive substance use, and social
instability such as homelessness or imprisonment [12].
In May 2016 the French Ministry of Health announced universal access to DAA [13].
Before this announcement, initiating DAA treatment was subject to a multidisciplinary con-
sultation meeting (RCP) which evaluated its relevance on a case by case basis [14]. Clinical cri-
teria were usually the basis for selecting patients for DAA treatment. We do not know to what
extent other patient characteristics, especially those that may limit patients’ acceptability of,
engagement in, or adherence to treatment, influenced selection for DAA initiation [10,15].
Injecting drug use is a well described factor which can delay HCV treatment initiation [16]. It
has also been reported that HCV-infected patients with psychiatric disorders are less likely to
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benefit from HCV treatment. In France, Roux et al [17] also reported that people who inject
drugs (PWID) (currently or in the past) were less likely to be treated for HCV in the PEG-IFN
era. However, a previous study using data collected during the ANRS CO13 HEPAVIH cohort
showed no relationship between a history of injecting drug use and access to PEG-IFN+ ribavi-
rin treatment [18]. While the HCV infection epidemic in France, and more generally in
Europe, has mainly been driven by injecting drug use [19], recent data suggest the epidemiol-
ogy of HCV infection in HIV patients is changing [20]. Given that national HCV guidelines
strongly recommend access to HCV treatment for HIV patients [14] and that free access to
DAA has been possible since May 2016 in France, we aimed to compare the socio-behavioral
characteristics of patients initiating HCV treatment in the ANRS CO13 HEPAVIH cohort
between those receiving PEG-IFN-based treatment and those receiving DAA, our hypothesis
being that patients’ characteristics may play an important role in caregiver-patient relation-
ships, as well as in access to and retention in the HCV and HIV care systems.
Our objective was not simply to identify possible barriers to accessing DAA treatment, but
also to highlight the change in the profile of HIV-HCV co-infected patients initiating HCV
treatment.
Methods
Study design and population
ANRS CO13 HEPAVIH is a multicenter observational cohort initiated in France in 2005
among HIV-HCV co-infected patients to characterize the natural history of co-infection in
terms of both morbidity and mortality and their determinants, and to better understand the
interactions between the two viruses and treatments [21]. ANRS CO13 HEPAVIH recruited
outpatients from 32 clinical centers in France who were aged 18 or over, had both chronic hep-
atitis C and HIV infection, had detectable plasma HCV RNA, were positive for anti-HCV anti-
bodies, and agreed to participate in the cohort (a signed letter of informed consent being
provided).
Patient recruitment for this cohort included three phases:
• The first phase between December 2005 and December 2008 recruited adult HIV-positive
patients, who were also either chronically infected by HCV at enrollment or had a negative
HCV RNA test by PCR six months after ending HCV treatment (PEG-IFN),
• The second phase, from September 2011 to March 2016, recruited both individuals who
spontaneously cleared HCV before the enrolment, and HIV-HCV infected patients who ini-
tiated HCV treatment with triple therapy (PEG-IFN +ribavirin + either telaprevir or
boceprevir),
• The third phase, from May 2014 to November 2015, was an additional recruitment phase,
where patients who were already receiving, or were scheduled to receive DAA within six
months, were recruited.
In France, PEG-IFN+ ribavirin first became available in 2000. Boceprevir and Telaprevir
became available in 2010. All three regimens were replaced from 2014 onwards with DAA.
In the present study, we included all cohort patients who had received or were still receiving
HCV treatment, whether PEG-IFN-based in the first phase of the cohort or DAA-based in the
third phase (Fig 1).
We preferred to exclude Phase 2 patients from this comparison for two reasons: first, a very
small sample were eligible for this study, mainly patients in a severe state of illness and patients
who were very unresponsive to Phase 1 treatment (ie PEG-IFN+Ribavirin) due to the high
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toxicity of this treatment. In addition, patients in the Phase 2 did not complete the annual self-
administered questionnaires.
Data collection
For patients included in the first recruitment phase, clinical visits were scheduled annually for
non-cirrhotic patients and every six months for cirrhotic patients. Collection of socio-behav-
ioral data using self-administered questionnaires (SAQ) was scheduled annually. For patients
initiating HCV treatment, additional visits were scheduled, before, during and after the end of
treatment. For patients included in the third recruitment phase receiving DAA, clinical and
biological data were collected at treatment initiation, at the end of treatment, and six months
Fig 1. Flow chart of the patients included in the study.
https://doi.org/10.1371/journal.pone.0199874.g001
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after the end of treatment, using medical questionnaires. These data included weight, blood
pressure, clinical stage of HIV infection, blood count, immuno-virological data, hepatic and
renal assessment values, HCV RNA PCR measurements, and data on HCV and HIV treat-
ments (drug, dosage, indication, initiation date and date of treatment end).
Socio-behavioral data were collected from SAQ at treatment initiation and at the end of
treatment. The SAQ included items concerning patients’ socio-demographic characteristics
and information on patients’ use of psychoactive drugs, tobacco, and alcohol (AUDIT-C).
Variables
Alcohol consumption. Alcohol consumption was measured using the AUDIT-C ques-
tionnaire. This scale is composed of three questions each of which having four possible
answers (i.e., a score ranging from 0 to 4; total scale score ranging from 0 to 12). Hazardous
alcohol consumption was defined as having a AUDIT-C score 4 for men or 3 for women
[22]. Binge drinking was defined as consuming six or more alcoholic drinks on any one occa-
sion during the previous month.
Drug use. Patients were asked about their consumption of the following psychoactive sub-
stances during the previous four weeks: cannabis, cocaine, crack, heroin, ecstasy, amphet-
amines, LSD. With regard to cannabis consumption, patients were classified into three
categories: “No use”, “non-regular use” and “regular or daily use.”
Tobacco consumption. Tobacco smoking (smoking status, history of smoking, number
of cigarettes per day) was assessed during face-to-face interviews with physicians for patients
in the first and second recruitment phases and using self-administered questionnaires for
patients from the third phase.
Unstable housing conditions. Patients who were neither tenant nor owner of their hous-
ing were considered to have unstable housing.
For the evaluation of liver fibrosis, we used the FIB4 index obtained by the following for-
mula [23]
Fib4 index ¼
Age ðyearÞAST ðU=LÞ
Platelets count ð109=LÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ALT ðU=LÞ
p
Severe fibrosis or cirrhosis was defined as a FIB-4 index score>3.25. A FIB-4 score between
1.45 and 3.25 corresponded to moderate fibrosis and <1.45 to no clinically significant fibrosis
[24]. A FIB-4 score above 1.45 corresponded to significant fibrosis.
Statistical analyses
Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, North
Carolina). The main characteristics of patients at HCV treatment initiation were compared
between patients initiating PEG-IFN-based treatment (Phase 1) and those initiating DAA
(Phase 3) (chi-square test for categorical variables, Student’s t test for continuous variables).
We used data from the SAQ completed at the visit closest to the date of treatment initiation for
patients receiving PEG-IFN treatment (Fig 1). For patients receiving DAA, we used data col-
lected during the visit scheduled at the beginning of treatment.
A multivariable analysis was then performed with logistic regression models, using a binary
variable indicating the type of treatment received (PEG-IFN vs DAA) as the dependent vari-
able. All significant variables with a p-value of<0.20 in the univariate analyses were intro-
duced into the multivariable regression model to estimate the adjusted effect and derive the
adjusted odds ratio (aOR) for each of the dependent variables. A 95% confidence level was also
estimated for each aOR.
Socio-behavioral characteristics between pegylated-interferon treated and DAA-treated patients
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In order to verify the robustness of the results and exclude possible recruitment phase bias, i.e.
the possibility that patients recruited in the third phase had a different pattern of socio-behavioral
characteristics from the patients in the first phase, a sensitivity analysis was conducted which
included only patients followed up in clinical centers involved in all three phases of the cohort.
Ethics statement
This study was approved by the "Comite´ de Protection des Personnes (CPP)" (Ref N˚ 2234 on
April 19th, 2005) and the “Commission Nationale de l’Information et des Liberte´s de France
(CNIL)” on September 6th, 2005. Participant provided signed, informed consent.
Results
Participants’ characteristics
A total of 580 HIV-HCV co-infected patients treated for chronic hepatitis C during the follow-
up were included in the study (Fig 1). Mean age was estimated at 47.8 years±7.6 (range 23 to
71 years). Most were male (75.9%; 439/578) and just under a fifth (17.4%; 99/569) had unstable
housing (Table 1).
Of the total patient sample, 233 (40.2%) were on DAA. These individuals were significantly
older than those who received PEG-IFN treatment (p = 0.0001) (Table 1). A significantly
higher proportion of patients who received PEG-IFN treatment (21.4%) had unstable housing
conditions (vs those receiving DAA (11.2%)) (p = 0.0016). (Table 1).
Addictive behaviors
Just under two-thirds (65.1%; 364/559) of the study population were active tobacco smokers.
No significant difference was observed between the two groups (Table 1).
Of the total study population, 27.8% (155/557) reported hazardous alcohol consumption
and 27.2% (151/555) binge drinking. No significant difference was detected between the two
groups of patients regarding hazardous alcohol consumption (29.1% among PEG-IFN-treated
patients vs 25.7% among DAA-treated patients, p = 0.3866) and binge drinking (27.3% vs
27.0%, p = 0.9362) (Table 1).
In terms of drug use, two-fifths of the total population (38.6%; 224/580) were drug users.
One-fifth were regular or daily cannabis users: 20.7% (107/516) (Table 1). Almost three-fifths
(56.7%; 317/559) had a history of drug injection. Although, the proportion of patients who
reported drug use was significantly higher in the PEG-IFN group (44.7% vs 29.6%, p = 0.0003),
the consumption of drugs other than cannabis did not differ between both treatment groups
(p = 0.98). The proportion of patients who reported regular cannabis consumption was signifi-
cantly lower in the DAA group (15.6% vs 24.3%, p = 0.0002). Moreover, the proportion of
patients with a history of drug injection was significantly higher in the PEG-IFN group (68.9%
vs 39.0%; p<0.0001) (Table 1). Finally, the proportion of patients with a history of drug injec-
tion was significantly higher among those who had unstable housing than among those who
did not (71.7% vs 54.4%, p = 0.0016).
In terms of clinical characteristics, two-thirds of the study population (65.5%) had signifi-
cant liver fibrosis. The proportion of patients with significant fibrosis was higher in the DAA
group (72.3% vs 62.4%, p = 0.0293) (Table 1).
Multivariable analysis
In the multivariable analysis, only age, unstable housing, cannabis use and a history of drug
injection remained associated with the type of HCV treatment received.
Socio-behavioral characteristics between pegylated-interferon treated and DAA-treated patients
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Table 1. Comparison of patients’ socio-behavioral profiles at HCV treatment initiation in the ANRS CO13 HEPAVIH cohort (N = 580).
Patients’ characteristics N (%) Univariate analysis Multivariable analysis
PEG-IFN treatment N (%) DAA treatment N (%) p-value aOR [95% CI]
HCV treatment 580 - - -
Peg-IFN 347 (59.8)
DAA 233 (40.2)
Age 572 347 225 0.0001 1.17 [1.13; 1.22]
Mean (SD) 47.8 (7.6) 45.1 (6.2) 52.00 (7.8)
Median (IQR) 48 (43–52) 45 (42–49) 52 (49–56)
Gender 578 347 231 0.270
Male 439 (75.9) 258 (74.4) 181 (78.4)
Female 139 (24.1) 89 (25.6) 50 (21.6)
Living in a couple 573 345 228 0.835
Yes 277 (48.3) 168 (48.7) 109 (47.8)
No 296 (51.7) 177 (51.3) 119 (52.2)
Unstable housing1 569 345 224 0.0016
Yes 99 (17.4) 74 (21.4) 25 (11.2) 0.46 [0.24; 0.88]
No 470 (82.6) 271 (78.6) 199 (88.8) 1
Plasma HIV-RNA <50 copies/ml 442 345 97 0.0003
Yes 372 (84.2) 279 (80.9) 93 (95.9)
No 70 (15.8) 66 (19.1) 4 (4.1)
CD4 count–cells/mm3 442 342 100 0.0007
Mean (SD) 511 (278) 474 (251) 641 (325)
Median (IQR) 462 (303–656) 430 (287–599) 628 (411–838)
HCV viral load, log10 UI/ml 364 265 99 <0.001
Mean (SD) 13.6 (2.1) 13.6 (2.3) 13.7 (1.5)
Median (IQR) 13.9 (12.8–15.0) 14 (12.7–15.2) 13.8 (13–14.7)
Tobacco smoking 559 328 231 0.0896
Yes 364 (65.1) 223 (68.0) 141 (61.0)
No 195 (34.9) 105 (32.0) 88 (39.0)
Hazardous alcohol consumption2 557 347 210 0.3866
Yes 155 (27.8) 101 (29.1) 54 (25.7)
No 402 (72.2) 246 (70.9) 156 (74.3)
Binge drinking3 555 344 211 0.9362
Yes 151 (27.2) 94 (27.3) 57 (27.0)
No 404 (72.8) 250 (72.7) 154 (73.0)
Drug use4 580 347 233 0.0003
Yes 224 (38.6) 155 (44.7) 69 (29.6)
No 356 (61.4) 192 (55.3) 164 (70.4)
Cannabis use 516 305 211 0.0002
No use 314 (60.9) 163 (53.4) 151 (71.6) 1
Non- regular use 95 (18.4) 68 (22.3) 27 (12.8) 0.41 [0.22; 0.77]
Regular or daily use 107 (20.7) 74 (24.3) 33 (15.6) 0.50 [0.28; 0.91]
Cocaine use 580 347 233 0.7647
Yes 37 (6.4) 23 (6.6) 14 (6.0)
No 543 (93.6) 324 (93.4) 219 (94.0)
Crack use 580 347 233 0.6875
Yes 4 (0.7) 2 (0.6) 2 (0.9)
No 576 (99.3) 345 (99.4) 231 (99.1)
(Continued)
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In our study sample, for each 1-year increase in age, patients were 17% more likely (aOR =
1.17 95% CI [1.13; 1.22]) to receive DAA treatment. In contrast, patients with unstable housing
were less likely to receive DAA treatment (0.46 [0.24; 0.88]) than PEG-IFN based regimens. With
respect to cannabis consumption (reference group: non-users), patients who used cannabis regu-
larly or daily were 50% less likely to receive DAA treatment than PEG-IFN based regimens (0.50
[0.28; 0.91]), while non-regular users were 59% less likely (0.41 [0.22; 0.77]) to receive DAA treat-
ment. Similarly, patients with a history of injecting drug use were 81% less likely to receive DAA
treatment (0.19 [0.12; 0.31]) than to receive PEG-IFN based regimens (Table 1).
Sensitivity analysis
In order to eliminate any possible selection bias arising from the fact that some centers fol-
lowed a greater number of HIV-HCV co-infected patients who used drugs, we performed a
sensitivity analysis which excluded clinical centers not involved in all 3 phases of the cohort,
Accordingly, only 27 clinical centers were included in the sensitivity analysis which led to 26
patients (4.4%) being excluded. The results of the sensitivity analysis confirmed those of the
main multivariable analysis (data not shown).
Table 1. (Continued)
Patients’ characteristics N (%) Univariate analysis Multivariable analysis
PEG-IFN treatment N (%) DAA treatment N (%) p-value aOR [95% CI]
Heroin/subutex use 580 347 233 0.1554
Yes 17 (2.9) 13 (3.8) 4 (1.7)
No 563 (97.1) 334 (96.3) 229 (98.3)
Ecstasy use 596 347 233 0.1091
Yes 19 (3.3) 8 (2.3) 11 (4.7)
No 561 (96.7) 339 (97.7) 222 (95.3)
Amphetamines use 580 347 233 0.0302
Yes 6 (1.0) 1 (0.3) 5 (2.2)
No 574 (99.0) 346 (99.7) 228 (97.8)
LSD use 580 347 233 0.5345
Yes 4 (0.7) 3 (0.9) 1 (0.4)
No 576 (99.3) 344 (99.1) 232 (99,6)
Significant liver fibrosis5 502 343 159 0.0293
Yes 329 (65.5) 214 (62.4) 115 (72.3)
No 173 (34.5) 129 (37.6) 44 (27.7)
Severe liver fibrosis or cirrhosis5 502 343 159 0.049
Yes 112 (22.3) 68 (19.8) 44 (27.7)
No 390 (77.7) 275 (80.2) 115 (72.3)
Drug injection history 559 331 228 <0.0001
Yes 317 (56.7) 228 (68.9) 89 (39.0) 0.19 [0.12; 0.31]
No 242 (43.3) 103 (31.1) 139 (61.0) 1
1 Unstable housing was defined as not being owner or tenant of one’s housing.
2 Hazardous alcohol consumption was defined as having an AUDIT-C score 4 for men or 3 for women
3 Binge drinking was defined as consuming six or more alcoholic drinks on any one occasion during the previous month.
4 Drug use was defined as the use of at least one of the following psychoactive substances during the previous four weeks: cannabis, cocaine, crack, heroin, ecstasy,
amphetamines, LSD.
5 Significant liver fibrosis was defined as a FIB-4 score >1.45, and severe fibrosis or cirrhosis as a FIB-4 score >3.25.
https://doi.org/10.1371/journal.pone.0199874.t001
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Discussion
Our analysis of data from the ANRS CO13 HEPAVIH cohort is the first to compare character-
istics of patients treated with first-generation HCV regimens with that of patients treated with
DAA. Interestingly, patients with unstable housing and a history of drug injection (factors
which both characterize vulnerable groups) and patients with regular cannabis use were all less
likely to receive DAA treatment than PEG-IFN-based regimens. Moreover, the sensitivity
analysis, which removed the possible recruitment effect, confirmed these results.
Given that there is no medical argument to delay providing a patient with DAA, as these
treatments extremely effective and safe, universal access to DAA should help to better control
the HCV epidemic [25]. In 2016, French policy makers stated universal access to HCV therapy,
given that all patients with chronic hepatitis C at any stage of liver fibrosis, and from all vulner-
able groups (i.e., HIV-HCV co-infected patients, people who use drugs, etc.), have the right to
access HCV treatment and care according to the recommendations by the French High
Authority in Health (HAS) (cf: http://www.has-sante.fr/portail/upload/docs/application/pdf/
2016-05/aad_avis_25052016_ct_25052016.pdf).
Our primary focus was to understand whether there were any differences between
HIV-HCV co-infected patients treated with DAA and those treated with PEG-IFN based regi-
mens in terms of socio-behavioral characteristics.
The association we found between less access to DAA and unstable housing is consistent
with prior studies [15] which reported that unstable housing is a barrier to initiation of chronic
hepatitis C treatment, as it could compromise adherence to treatment. People with unstable
housing are also more likely to have poorer financial and psychosocial statuses. Therefore,
they are not only at a high risk of HCV infection [26], but are also exposed to discrimination,
social isolation and sometimes rejection. Given this, the fear of rejection might affect patient-
provider relationships, and this may not regularly seek medical care and often miss follow-up
visits in HIV medical centers. Patients with unstable housing are known to be less likely to
have a long-term commitment to continued medical care for HIV and other comorbidities,
including HCV infection [27]. There is also the risk that some health workers mistrust of
patients may contribute to delayed access to care, including HCV treatment with DAA. In
addition to factors related to the price of DAA, to caregivers and to the healthcare system itself
[28,29], in our study, it is possible that the majority of HIV-HCV co-infected patients with
unstable housing conditions were treated and cured in the era of PEG-IFN. That could be the
result of policy efforts to treating vulnerable populations.
PWID constitute a key group where the prevalence of chronic hepatitis C is high, due to
shared injection equipment [30]. In French and international (cf http://www.eacsociety.org/
files/guidelines_8_0-english_web.pdf) guidelines, HCV treatment with DAA is strongly rec-
ommended for HIV-HCV co-infected patients and drug users, irrespective of disease stage, as
it constitutes an important tool for prevention of HCV transmission. Previous studies on HCV
mono-infected and HIV-HCV co-infected PWID showed high rates of sustained virological
response (SVR) to HCV treatment in these populations, and also showed that PWID did not
exhibit lower rates of adherence to treatment than other patients [31–33]. Another issue with
PWID is the risk of reinfection after SVR to HCV treatment. Despite the relatively low rate of
reinfection among co-infected patients, estimated at 1%-5%, in one study [34], this rate can
still have an impact at the population level and compromise the global eradication of HCV
[35]. Although one study highlighted that HIV-HCV co-infected PWID in France are not less
likely to be treated with PEG-IFN based regimens [18], another French study [17] found the
opposite. Our results showed that this population is less represented among DAA-treated
patients, which could suggest they have less access to this new treatment [36]. In a Canadian
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HIV-HCV co-infected cohort, Saeed et al. [37], found great disparities in DAA initiation, and
highlighted that marginalized populations, including PWID, were less likely to initiate HCV
treatment in the DAA era.
Some physicians may tend to delay HCV treatment in active users of psychoactive sub-
stances, including cannabis, because of concerns about poor adherence to treatment and the
high risk of re-infection after treatment [38,39]. However, research has shown that patients
using cannabis often do so to relieve a range of troublesome side effects of PEG-IFN-treatment
[40]. In addition, regular cannabis use is frequent in former injecting drug users and more par-
ticularly in former opioid-dependent individuals, as it relieves opioid withdrawal symptoms
and HIV-HCV-related symptoms [41,42]. In the present study, we also found that the propor-
tion of cannabis users was lower in individuals receiving DAA, suggesting either that cannabis
users had already been treated with PEG-IFN based treatment or that cannabis users have
reduced access to DAA. Cannabis use is an additional proxy of history of drug use or unstable
lifestyles. Most drug users in our study were treated with PEG-IFN or with DAA. Yet, to be
effective, the management of these patients has to go beyond simply providing medical treat-
ment. Substance abuse requires integrated, multidisciplinary care. Promoting stable housing
through a "housing first" approach also seems to be crucial [43,44]. The results of this study
also showed that older patients were more likely to receive DAA treatment than PEG-IFN–
based regimens. This population included individuals who did not respond to PEG-IFN, and
others whose advanced stage of liver disease (advanced fibrosis or cirrhosis, hepatocellular car-
cinoma) was a criterion to schedule treatment. This was highlighted by the difference in liver
fibrosis found when comparing the two groups in univariate analysis. According to the natural
history of chronic hepatitis C in patients infected with HIV, the occurrence of severe complica-
tions, including liver fibrosis or cirrhosis, is strongly associated with patient age [42] and this
could influence HCV treatment SVR rates [45,46].
The results from our cohort study need to be further explored in a qualitative manner, from
the perspective of both patients and caregivers [19], in order to better identify their beliefs and
perceptions and to acquire a greater understanding of the reasons for delayed DAA initiation
in some groups. The sensitivity analysis confirmed results from the main multivariable analy-
sis. Current guidelines for access to HCV treatment in France stipulate that HIV-HCV co-
infected patients and all vulnerable populations, including PWID, should be treated. However,
our results suggest that this is not yet a reality. Indeed, since DAA are more effective and less
toxic than PEG-IFN-based treatments, they should be accessible to more PWID, especially
those who are most socially vulnerable, as this population is the reservoir of the HCV epi-
demic, facilitating HCV transmission in their network through risky practices [34].
Overall, the high prices which pharmaceutical firms ask for DAA may influence health pol-
icy decisions, and force clinicians to delay treatment initiation until liver fibrosis is already
quite advanced. That could explain the fact that vulnerable and marginalized populations were
less represented in patients receiving DAA. Such decisions are unacceptable now that chronic
hepatitis C is a curable disease and that DAA have been proven to be cost-effective [47]. Before
the advent of DAA, access to treatment for chronic hepatitis C was very selective in France,
with priority being given to patients at an advanced stage of the disease and those with compli-
cations including liver fibrosis and hepatocellular carcinoma. It was the consensus that every-
one has the right to benefit from HCV medical care [48] which led to the French government
adopting a policy of universal HCV care in May 2016.
Overall, the results of this study highlighted a change over time in the profile of HIV-HCV
co-infected patients treated for HCV infection in France. This evolution reflects improvements
in the treatment of hepatitis C in France, as patients from the most vulnerable populations can
now access treatment and therefore be cured.
Socio-behavioral characteristics between pegylated-interferon treated and DAA-treated patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0199874 July 5, 2018 10 / 15
Our study has limitations. First, we compared access to HCV treatment between patients
treated at two different calendar periods, and consequently there may have been changes in
the epidemiological characteristics of patients recruited. However, to tackle this potential bias,
we performed a sensitivity analysis which confirmed the results found. Second, behaviors were
based on self-reports which can be affected by social desirability bias. Nevertheless, even if
some under-reporting were present, it is unlikely that this would vary over time and affect the
comparison between access to treatment in the PEG-IFN and DAA period. Finally, given that
is an observational cohort, it may be not appropriate to extrapolate these findings to all
HIV-HCV co-infected patients in France.
Conclusion
In this study, people with unstable housing conditions, those with a history of drug injection
and cannabis users were all less represented among patients who initiated DAA treatment
than among those who initiated PEG-IFN-based regimens. It is possible that a majority of
these patients had previously been treated for HCV in the PEG-IFN era. This reflects a change
in the epidemiological profile of HIV-HCV co-infected patients receiving HCV treatment in
France. As HCV treatment is prevention, improving access to DAA, in particular to individu-
als with high-risk behaviors, remains a major clinical and public health strategy.
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